The economic impact of peanut allergies
1Vice President, Pharmacy Benefits, SelectHealth, Murray, UT.
Insights
Peanut allergies in children are rising, causing significant costs and health risks. New biologic treatments offer promise but pose challenges for insurance coverage and integration into care.
Area of Science:
- Allergy and Immunology
- Pediatric Health
- Pharmacoeconomics
Background:
- Peanut allergy is the most common childhood food allergy, affecting up to 2.5% of children, with a threefold increase in prevalence over 20 years.
- Peanut allergies incur substantial medical, financial, and societal costs and are a leading cause of fatal food allergy reactions in children.
- Current treatments like oral immunotherapy have limitations, including lengthy intervention periods and lack of standardized protocols.
Purpose of the Study:
- To explore the potential impact of biologic compounds on managing pediatric peanut allergies.
- To address the economic considerations and formulary integration challenges associated with novel biologic therapies for peanut allergy.
Main Methods:
- This abstract does not detail specific methods but discusses the implications of introducing new biologic treatments.
- Analysis of current trends in peanut allergy prevalence, associated costs, and existing treatment modalities.
- Consideration of the economic and logistical challenges for healthcare payers regarding new therapies.
Main Results:
- Biologic compounds represent a potential paradigm shift in managing peanut allergy.
- The high anticipated cost of these biologics presents significant challenges for healthcare payers in terms of formulary placement and treatment pathways.
- Further research and standardized protocols are needed to optimize the integration of these advanced treatments.
Conclusions:
- Biologic therapies hold promise for revolutionizing peanut allergy management in children.
- Careful consideration of cost-effectiveness and payer strategies is crucial for the successful implementation of these novel treatments.
- Addressing the economic and logistical hurdles will be key to ensuring patient access to potentially life-changing peanut allergy therapies.
Abstract:
The prevalence of peanut allergies, the most common food allergy in children, has tripled in the past 2 decades. Today, up to 2.5% of the pediatric population has been diagnosed with a peanut allergy. Peanut allergies result in significant medical, out-of-pocket, and opportunity costs to payers, parents, and employers. They are also a leading cause of food allergy-related deaths in children. Although there is evidence that peanut oral immunotherapy may be effective in reducing the severity of the allergy, such approaches require a long intervention with no standardized protocol available. The introduction of biologic compounds to treat peanut allergies has the potential to revolutionize how these patient cases are managed. Their anticipated high cost, however, raises several issues for payers as to how to integrate these new therapies into formularies and treatment continuums.
Related Concept Videos
01:19Impact of Groups on Groups
01:30Impact
When particles with different initial velocities collide, they induce deformation by applying equal and opposite impulses. At the point of maximum deformation, the particles move together with...
01:28Impact of Groups on Individuals
01:25Impact of Individuals on a Group
01:30Impact of Schemas
01:30Types of Impact
The coefficient of restitution is a metric for understanding the dynamics of impacts. It quantifies the ratio of relative velocity...